1284 - Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Gerald Pierone, Jr., MD (he/him/his)

Medical Director
Whole Family Health Center
Vero Beach, Florida, United States

Jennifer S. Fusco, BS

Chief Science Officer
Epividian, Inc.
Durham, North Carolina, United States
LB

Laurence Brunet, PhD

Director of Epidemiology
Epividian, Inc.
Durham, North Carolina, United States
Vani Vannappagari, MBBS, MPH, PhD

Global Head, Epidemiology & Real World Evidence
ViiV Healthcare
Research Triangle Park, North Carolina, United States
SS

Supriya Sarkar, PhD, MPH

Director, Epidemiology and Real World Evidence
ViiV Healthcare
Baltimore, Maryland, United States
CH

Cassidy Henegar, PhD, MSPH

Director
ViiV Healthcare
Chapel Hill, North Carolina, United States
Jv

Jean A. van Wyk, MB,ChB; MFPM

Global Medical Lead, VP
ViiV Healthcare Limited
Brentford, England, United Kingdom
AZ

Andrew Zolopa, MD

Head of North America Medical Affairs
ViiV Healthcare
Portola Valley, California, United States
GF

Gregory P. Fusco, MD, MPH

Chief Executive Officer & Chief Medical Officer
Epividian, Inc.
Durham, North Carolina, United States